A shadow market for unapproved slimming medications is propelled by social media fitness personalities and sellers on messaging platforms, based on new investigations.
Experimental Treatment Gaining Popularity Online
Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its alleged fat-burning properties. Followers are encouraged to message these profiles privately for source information, while also obtaining promotional offers.
Thriving Commerce on Social Networks
Additionally, a robust trade exists on messaging services, where communities with numerous of participants share “before and after” images, administration instructions and assertions of rapid British shipping. Vendors market the substance there before directing buyers to WhatsApp for transactions.
Understanding The Experimental Drug
This medication is an investigational injection created by US drugmaker Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, GIP and glucagon. Early trials suggest it could help patients lose up to a quarter of their total weight. Nicknamed the “triple G”, the substance is being promoted digitally as the next Ozempic.
Healthcare Professionals Express Worries
Nevertheless, physicians and pharmacists have warned that the sale of what remains an unlicensed drug in the UK is a cause for concern and could lead to users administering products of uncertain source.
Some professionals stated the demand for the experimental drug could be linked to the rising cost of licensed slimming treatments such as Mounjaro.
Legal Position and Implementation
Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unlicensed medication that must not be marketed or distributed for personal consumption under the British medical regulations.
Several influencers try to sidestep the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still breach pharmaceutical, advertising, and consumer laws, risking penalties, prosecution or imprisonment.
Service Response and Content Elimination
According to TikTok, the platform has taken down problematic material and banned associated keywords and query recommendations. The organization said it was dedicated to maintaining the platform secure and allocating resources in strengthening compliance measures.
Digital Trading Activities
Investigations also found communities with up to 9,000 members marketing retatrutide using the platform's built-in discovery tool, which operates like a online catalog. Entering “retatrutide” instantly brings up groups with thousands of members, populated with images of weight loss, glowing testimonials and detailed guides for preparing or administering at home.
After minutes of entering one community, a vendor posted contact information, where the majority of transactions occur. The seller provided an instruction manual and guaranteed shipping within 48 hours. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another provided a photo of a alleged testing documentation. Not one asked about weight, health issues or previous experience.
Item Information and Pricing
Inside these communities, posts display black plastic packages with postal service stickers, claiming to contain new batches. One message read: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, prepared at home with purified liquid, or ready-to-use injectors typically priced at £160 for 20mg. When asked how much time a pen should last, vendors give contradictory responses varying between a few weeks to “depends on your body”.
Service Moderation and Security Measures
A spokesperson for the messaging service stated it regularly moderated harmful material on its platform including material that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“People are administering materials they cannot confirm. Even if the research behind this drug is sound, these digital versions may not contain what they advertise,” said a pharmacy expert, the director of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of Asda Online Doctor connected the surge in demand to recent price rises for approved weight-loss drugs such as Mounjaro. “With prices rising, patients are turning to online platforms. But counterfeit treatments are extremely risky. You cannot know what’s contained or whether the conditions they were produced in was clean,” she said.
Her team has previously encountered patients injured by self-injection from unconfirmed suppliers. “We understand the disappointment, but purchasing from messaging apps or communication platforms is gambling with your health,” stated the doctor. “These substances could be contaminated or incorrectly dosed.”
Manufacturer Position
A representative from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or authorized by any regulatory agency globally. “Therefore at this time no one can sell [it] for human use,” they explained, adding that any item “misleadingly claiming itself as a Lilly investigational substance not yet authorized … may expose users to potentially significant health risks”.
